Cancer Treatment Trial Results

Phase I/II Melanoma Personalized Cancer Vaccine Trial

Demographics
demographics

*One patient excluded for recurrence prior to 12 week F/U (19 days); one patient lost to F/U

Toxicity
toxicity
Overall survival
overall-survival
Gender
gender
Age
age
Initial Stage IV
initial-stage-iv
Initial Stage I
initial-stage-i
Time to treatment
time-to-treatment
Overall survival
overall-survival-2
No evidence of disease (NED)
ned
# Inoculation
inoculations

US FDA Trials